When Should Tysabri Patients Be Evaluated for PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

General Health Context and Transition to Specific Risk

If you or a loved one is taking Tysabri, you may wonder when doctors typically start discussing the risk of progressive multifocal leukoencephalopathy (PML). This evaluation is often considered early in treatment and at regular intervals, especially if certain risk factors are present. The medical and scientific community has long recognized the importance of balancing therapeutic benefit with potential adverse outcomes, and this page outlines when PML screening is commonly discussed in clinical practice.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance. The clinical presentation of PML is characterized by progressive neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis typically involves brain MRI showing white matter lesions and detection of JCV DNA in cerebrospinal fluid. The disease is often fatal or results in severe disability, as noted in the boxed warning. Tysabri's pharmacology involves binding to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in the central nervous system but also impairs immune surveillance, allowing latent JCV to reactivate and cause PML. The label identifies three risk factors for PML: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

Clinical Trial Data and Causation

In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data establish a causal link between Tysabri and PML, as the infection is rare in immunocompetent individuals and occurred at higher rates in treated populations. The mechanistic pathway linking Tysabri to PML involves reduced immune surveillance in the brain. By blocking leukocyte migration, Tysabri decreases the ability of the immune system to control JCV replication. This allows the virus to infect oligodendrocytes, leading to demyelination and neurological damage. The risk is highest in patients with anti-JCV antibodies, indicating prior exposure to the virus. Regarding risk anchors, the adequacy of warnings is addressed by the boxed warning and the TOUCH Prescribing Program, a restricted distribution program that requires prescribers and patients to be enrolled and to follow monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, PML remains a serious risk, and patients should be informed of the symptoms and the need for prompt medical evaluation.

Risk Factors and Patient Management

Causation considerations for affected patients include the presence of risk factors and the timeline of exposure. PML typically occurs after prolonged treatment, with risk increasing beyond two years. However, cases have been reported earlier, as seen in the Crohn's disease patient who developed PML after eight doses. The label emphasizes that the expected benefit must be sufficient to offset the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, discontinuation of Tysabri is necessary, and treatment may include plasma exchange to accelerate drug clearance. The timeline between exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient. Postmarketing data have shown cases after shorter durations, particularly in patients with additional risk factors. The label advises that monitoring should continue throughout treatment and after discontinuation, as PML can develop after stopping Tysabri. In summary, the evidence demonstrates that Tysabri causes PML through a well-understood mechanism involving impaired immune surveillance. The risk is increased by anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. Warnings are prominently displayed in the prescribing information, and a restricted distribution program is in place to mitigate risk. Patients and healthcare providers must remain vigilant for symptoms of PML, as early detection and intervention may improve outcomes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Tysabri increases PML risk?

Tysabri binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This reduces immune surveillance in the brain, allowing latent JC virus to reactivate and cause PML. The risk is highest in patients with anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML and how is it diagnosed?

PML presents with progressive neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis involves brain MRI showing white matter lesions and detection of JCV DNA in cerebrospinal fluid. Early detection is critical as the disease is often fatal or leads to severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How common is PML in Tysabri-treated patients?

In clinical trials, PML occurred in 3 out of 2912 patients (2 in MS patients, 1 in Crohn's disease). Postmarketing data show additional cases, with risk increasing after two years of treatment. The overall incidence is low but serious, and the boxed warning highlights the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.